LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

Home・Elenco Azioni・Zai Lab Ltd ADR

Zai Lab Ltd ADR

Chiusa

SettoreSettore sanitario

16.6 0.67

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

16.2

Massimo

16.7

Metriche Chiave
By Trading Economics
Entrata	-607K -51M
Vendite	-28M 100M
EPS	-0.46
Margine di Profitto	-51.215
Dipendenti	1,784
EBITDA	4.1M -44M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+94.95% upside

Dividendi
By Dow Jones
Utili prossimi	6 ago 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	-541M 1.8B
Apertura precedente	15.93
Chiusura precedente	16.6

Notizie sul Sentiment di mercato

By Acuity

34%

66%

94 / 344 Classifica in Healthcare

Zai Lab Ltd ADR Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

8 giu 2026, 22:20 UTC

Acquisizioni, Fusioni, Takeovers

Salesforce to Buy m3ter in Nod Toward AI-Native Business Models

8 giu 2026, 15:41 UTC

I principali Market Mover

American Battery Shares Jump on Energy Department Victory

8 giu 2026, 23:46 UTC

Discorsi di Mercato

Nikkei May Rebound After Monday's Selloff -- Market Talk

8 giu 2026, 23:37 UTC

Discorsi di Mercato

Oil Edges Higher Amid Ongoing Supply Disruption Concerns -- Market Talk

8 giu 2026, 23:25 UTC

Discorsi di Mercato

Should Australia Consider State-Linked Commodities Export Desk? -- Market Talk

8 giu 2026, 23:25 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

8 giu 2026, 21:57 UTC

Acquisizioni, Fusioni, Takeovers

Salesforce Expects to Close Deal in 2Q of Fiscal 2027

8 giu 2026, 21:56 UTC

Acquisizioni, Fusioni, Takeovers

Salesforce Agrees to Buy m3ter

8 giu 2026, 20:50 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

8 giu 2026, 19:22 UTC

Discorsi di Mercato

Oil Settles Higher as Israel-Iran Exchanges Raise Tension -- Market Talk

8 giu 2026, 19:01 UTC

Discorsi di Mercato

U.S. Natural Gas Futures Pull Back on Weather Outlook -- Market Talk

8 giu 2026, 18:52 UTC

Discorsi di Mercato

Global Energy Roundup: Market Talk

8 giu 2026, 18:52 UTC

Discorsi di Mercato

CAD Needs Trade Deal to Trigger Sustained Rally -- Market Talk

8 giu 2026, 18:17 UTC

Discorsi di Mercato

Oil Pulls Back Further As Iran, Israel Put Strikes on Hold -- Market Talk

8 giu 2026, 17:32 UTC

Discorsi di Mercato

Bank of Canada Should Incorporate Unemployment Rate Into Its Forecast -- Market Talk

8 giu 2026, 17:29 UTC

Discorsi di Mercato

Crypto Market Still Stays in 'Extreme Fear' Amid Rebound -- Market Talk

8 giu 2026, 17:29 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

8 giu 2026, 16:55 UTC

Acquisizioni, Fusioni, Takeovers

Monte dei Paschi: Mediobanca Integration Proceeding According to Plan

8 giu 2026, 16:54 UTC

Acquisizioni, Fusioni, Takeovers

Monte dei Paschi to Review Proposals From Banco BPM, Intesa Sanpaolo

8 giu 2026, 16:40 UTC

Discorsi di Mercato

Cryptocurrencies Rise After Iran and Israel Halt Exchanges of Fire -- Market Talk

8 giu 2026, 16:31 UTC

Discorsi di Mercato

No Recession in Canada, Scotiabank's CEO Says -- Market Talk

8 giu 2026, 16:27 UTC

Discorsi di Mercato

Mexican Inflation Seen Easing in May -- Market Talk

8 giu 2026, 16:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

8 giu 2026, 16:03 UTC

Acquisizioni, Fusioni, Takeovers

Orange Bought Stake From Lorca

8 giu 2026, 16:01 UTC

Acquisizioni, Fusioni, Takeovers

Orange Completes Acquisition of Remaining 50% Stake in MasOrange

8 giu 2026, 16:01 UTC

Acquisizioni, Fusioni, Takeovers

Orange Acquires 100% Ownership of MasOrange

8 giu 2026, 15:58 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

8 giu 2026, 15:58 UTC

Discorsi di Mercato

Gold Trims Losses After Israel, Iran Halt Exchanges of Fire -- Market Talk

8 giu 2026, 15:55 UTC

Discorsi di Mercato

Markets Price Small Chance USMCA Will Be Dismantled -- Market Talk

8 giu 2026, 15:41 UTC

Discorsi di Mercato

Gold Falls Below 200-Day Moving Average -- Market Talk

Confronto tra pari

Modifica del prezzo

Zai Lab Ltd ADR Previsione

Obiettivo di Prezzo

By TipRanks

94.95% in crescita

Previsioni per 12 mesi

Media 32.4 USD 94.95%

Alto 44 USD

Basso 21.6 USD

Basato su 4 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Zai Lab Ltd ADR - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

4 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 4 che hanno fornito valutazioni azionarie a Zai Lab Ltd ADR - Dist negli ultimi 3 mesi.

Sentiment

By Acuity

94 / 344 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Zai Lab Ltd ADR

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China.